Søgning på udtrykket 'rsv' giver 44 resultater
Kalender [2] Nyt fra tidsskrifterne [+20] Aktuelle smitsomme sygdomme [+20]
…er som følger: 1) Det vises for første gang, at et medikament kan reaktivere latent HIV-virus under samtidig HAART-behandling i en grad, så virus kan påvises i perifert blod. 2) Der er (omend videnskaligt svage) indicier på, at HIV-reservoir kan reduceres hos nogle patienter, og at effekten af det innate immunforsvar er af betydning herfor. 3) Det er den første originalartikel trykt i den allerførste udgave af et helt nyt HIV-tidsskrift (som formentlig vil blive et betydende tidsskrift på området).
…n (per oralt) blev undersøgt på ca. 700 Vietnamesiske patienter. Men der kunne desværre ikke erkendes nogen forskel i de to grupper. I en leder i samme nummer af NEJM henleder Peter Donald opmærksomheden på de gode behandlingsresultater man har i Cape Town med et kun 6 måneders regime som inkluderer Ethionamid (Trecator), Isoniazid, Rifamipcin og Pyrazinamid. Hvem har herefter opskriften på et nyt, etisk forsvarligt, klinisk studie til behandling af en af de mest alvorlige neuroinfektioner vi kender?
Kalender [2]
14. maj, Auditorium 3 og 4, Hvidovre Hospital
24. august 2023, Emil Aarestrup Auditorium, Odense Universitetshospital
Nyt fra tidsskrifterne [+20]
Der er mere end 20 resultater, måske du vil se flere resultater her?Journal of Medical Virology
16.07.2024
Journal of Medical Virology, Volume 96, Issue 7, July 2024.
Journal of Infectious Diseases
8.07.2024
Abstract . Background . A single-dose investigational respiratory syncytial virus (RSV) vaccine, RSV prefusion protein F3 (RSVPreF3), was co-administered with a single-dose quadrivalent influenza vaccine (FLU-D-QIV) in a phase 3, randomized, controlled, multicenter study in healthy, non-pregnant women aged 18–49 years.Methods . The study was observer-blind to evaluate the lot-to-lot consistency of RSVPreF3, and single-blind to evaluate the immune response, safety, and reactogenicity of RSVPreF3 co-adminis…
Journal of Infectious Diseases
29.06.2024
Abstract . Background . We conducted a global comprehensive literature review of observational studies reporting RSV incidence in adults and determined current evidence gaps.Methods . PubMed and Embase were searched for English-language publications (2000-2022) and congress abstracts (2019-2021) reporting RSV incidence rates/cumulative incidence. Cross-sectional studies, case series, and other designs estimating only RSV frequency were excluded. The search included all geographic areas; data were extracted …
BMC Infectious Diseases
27.06.2024
. Abstract. . Background. Annual epidemics of respiratory syncytial virus (RSV) had consistent timing and intensity between seasons prior to the SARS-CoV-2 pandemic (COVID-19). However, starting in April 2020, RSV seasonal activity declined due to COVID-19 non-pharmaceutical interventions (NPIs) before re-emerging after relaxation of NPIs. We described the unusual patterns of RSV epidemics that occurred in multiple subsequen…
BMC Infectious Diseases
23.06.2024
…ct. . Background. Although administrative claims data have a high degree of completeness, not all medically attended Respiratory Syncytial Virus-associated lower respiratory tract infections (RSV-LRTIs) are tested or coded for their causative agent. We sought to determine the attribution of RSV to LRTI in claims data via modeling of temporal changes in LRTI rates against surveillance data. . . . …
Clinical Infectious Diseases
6.06.2024
Abstract . Background . Data on the true prevalence of RSV among medically-attended acute respiratory illnesses (MAARI) has been limited by the lack of regular clinical testing of mild to moderate illnesses. Here we present a prospective evaluation of the epidemiology of RSV-associated MAARI across age groups and multimorbidity status over three seasons, which is informative in light of the recommendations for shared decision-making for vaccination in older adults.Methods . Ambulatory patients ≥6 months o…
Lancet Infectious Diseases
25.05.2024
Ad26.RSV.preF–RSV preF protein maintained high efficacy against RSV LRTD in older adults across three RSV seasons.
Lancet Microbe
16.05.2024
With recent studies showing nirsevimab infant immunisation significantly reduced respiratory syncytial virus (RSV)-related hospital admissions, and a maternal vaccine associated with significantly fewer RSV infections in infants, the outlook for RSV prevention in children is encouraging.
Journal of the American Medical Association
10.05.2024
A vaccine given during pregnancy that prevents respiratory syncytial virus (RSV) in infants was about 66% effective at protecting against RSV-associated respiratory illness, and about 69% effective at protecting against severe disease, according to a study in the New England Journal of Medicine. The data came from a randomized clinical trial involving more than 5000 pregnant people and their infants in 24 countries.
The Lancet Microbe
8.05.2024
With recent studies showing nirsevimab infant immunisation significantly reduced respiratory syncytial virus (RSV)-related hospital admissions, and a maternal vaccine associated with significantly fewer RSV infections in infants, the outlook for RSV prevention in children is encouraging.
Journal of Infectious Diseases
20.04.2024
Abstract . Respiratory syncytial virus (RSV) causes severe infections in infants, immunocompromised or elderly individuals resulting in annual epidemics of respiratory disease. Currently, limited clinical surveillance and the lack of predictable seasonal dynamics limits the public health response. Wastewater-based epidemiology (WBE) has recently been used globally as a key metric in determining prevalence of SARS-CoV-2 in the community but its application to other respiratory viruses is limited. In this stu…
BMC Infectious Diseases
12.04.2024
. Abstract. . Background. Respiratory syncytial virus (RSV) infection in children under 5 years have a significant clinical burden, also in primary care settings. This study investigates the epidemiology and burden of RSV in Italian children during the 2019/20 pre-pandemic winter season. . . . Methods. A prospective cohort study was conducte…
Journal of Medical Virology
2.04.2024
Journal of Medical Virology, Volume 96, Issue 4, April 2024.
Clinical Microbiology and Infection
15.03.2024
Each winter season, approximately 30% of infants younger than 1 year develop lower respiratory tract infections (LRTI), with the respiratory syncytial virus (RSV) the pathogen most frequently involved (1). As the main cause of hospitalization in infants and young children worldwide, LRTI disrupts health-care systems substantially (2).
New England Journal of Medicine
14.03.2024
New England Journal of Medicine, Volume 390, Issue 11, Page 1009-1021, March 2024.
New England Journal of Medicine
14.03.2024
New England Journal of Medicine, Volume 390, Issue 11, Page 1050-1051, March 2024.
Journal of Infectious Diseases
23.02.2024
Abstract . Background . An mRNA-based RSV vaccine, mRNA-1345, is under clinical investigation to address RSV disease burden in older adults.Methods . This phase 1, randomized, observer-blind, placebo-controlled, dose-ranging study evaluated safety, reactogenicity, and immunogenicity of mRNA-1345 in adults 65-79 years (NCT04528719). Participants were randomized to receive 1-dose of mRNA-1345 (12.5, 25, 50, 100, or 200-µg) or placebo and matched mRNA-1345 booster or placebo at 12-months.Results . Overall, 29…
Journal of Medical Virology
21.02.2024
Journal of Medical Virology, Volume 96, Issue 2, February 2024.
Journal of Infectious Diseases
2.02.2024
Abstract . Background . Respiratory syncytial virus (RSV) presents a global health concern. A lipid nanoparticle-encapsulated mRNA-based RSV vaccine (mRNA-1345) encoding the membrane-anchored RSV prefusion stabilised F glycoprotein (preF) is under clinical investigation.Methods . This phase 1, randomized, observer-blind, placebo-controlled dose escalation study assessed safety and immunogenicity of mRNA-1345 in healthy adults aged 18-49 years (NCT04528719). Participants were randomized to receive one dose o…
Aktuelle smitsomme sygdomme [+20]
Der er mere end 20 resultater, måske du vil se flere resultater her?Medscape Infectious Diseases
24.07.2024
Merck's antibody-based shot met the main goal of a mid-to-late stage trial, when tested to protect infants against a disease caused by the respiratory syncytial virus (RSV),. . Reuters Health Information
Medscape Infectious Diseases
3.07.2024
The RSV season is peaking earlier and entailing higher rates of hospitalization, according to Canadian data. . Medscape Medical News
Medscape Infectious Diseases
28.06.2024
Moderna's mRNA vaccine mRESVIA has been recommended for a marketing authorization in the EU to protect against respiratory syncytial virus in older adults. . Medscape Medical News
Medscape Infectious Diseases
28.06.2024
The U.S. CDC on Wednesday narrowed its recommendation for use of respiratory syncytial virus vaccines in older adults this year and held off on recommending their use for. . Reuters Health Information
Medscape Infectious Diseases
4.06.2024
For the first time, an mRNA vaccine has been approved for an indication other than COVID-19. The vaccine will join a couple other immunizations currently on the market for respiratory syncytial virus. . Medscape Medical News
Eurosurveillance latest updates
17.05.2024
.
Medscape Infectious Diseases
16.05.2024
Data raise questions about whether more testing for RSV and more vaccination are needed. . Medscape Medical News
Medscape Infectious Diseases
19.04.2024
Last year saw more than 50 new drug approvals, many of which may help internists better manage several common conditions in their patients. . Medscape Medical News
Eurosurveillance latest updates
12.04.2024
…ropean Mortality Monitoring Network (EuroMOMO) has observed excess mortality in Europe. During weeks 48 2023–6 2024, preliminary results show a substantially increased rate of 95.3 (95% CI: 91.7–98.9) excess all-cause deaths per 100,000 person-years for all ages. This excess mortality is seen in adults aged 45 years and older, and coincides with widespread presence of COVID-19, influenza and respiratory syncytial virus (RSV) observed in many European countries during the 2023/24 winter season. .
Medscape Infectious Diseases
10.04.2024
Pfizer said on Tuesday its respiratory syncytial virus (RSV) vaccine Abrysvo was well tolerated and generated an immune response in higher risk adults under the age of 60. . Reuters Health Information
Eurosurveillance latest updates
29.03.2024
. Background. Non-pharmaceutical interventions (NPIs) during the COVID-19 pandemic affected respiratory syncytial virus (RSV) circulation worldwide. . . Aim. To describe, for children aged
Medscape Infectious Diseases
20.03.2024
Adult RSV infection can have serious consequences. These five things to know will help you recognize and protect the adult populations most vulnerable to severe disease. . Medscape Infectious Diseases
Medscape Infectious Diseases
14.03.2024
With a maternal vaccine already on the market to protect newborns from RSV, the outlook for another looked promising, but latest phase 3 trial of a new candidate is now halted over safety concerns. . Medscape Medical News
Medscape Infectious Diseases
8.03.2024
(Corrects typo in CDC agency's name in paragraph 1) . Reuters Health Information
Medscape Infectious Diseases
2.03.2024
Pfizer on Thursday said a single dose of its new respiratory syncytial virus (RSV) vaccine Abrysvo maintained its ability to protect against the illness through a second. . Reuters Health Information
Eurosurveillance latest updates
2.02.2024
. Background. There is currently no standardised approach to estimate respiratory syncytial virus (RSV) epidemics’ timing (or seasonality), a critical information for their effective prevention and control. . . Aim. We aimed to provide an overview of methods to define RSV seasonality and identify factors supporting method choice or interpretation/comparison of seasonal estimates. . . Methods. We systematically searched PubMed and Embase (2016–2021) for studies using quantitative approaches to dete…
Medscape Infectious Diseases
1.02.2024
Amid the current winter wave surge of respiratory virus cases, how challenging is it for physician's to distinguish between, diagnose, and treat COVID-19 vs RSV and influenza? . Medscape Medical News
Eurosurveillance latest updates
26.01.2024
After Luxembourg introduced nirsevimab immunisation against respiratory syncytial virus (RSV), estimated neonatal coverage was 84% (1,277 doses/1,524 births) in 2023. That year, paediatric RSV-related hospitalisations, especially concerning infants
Medscape Infectious Diseases
6.12.2023
COVID-19 appears to be heading for a holiday season increase across most of the United States. . WebMD Health News
Medscape Infectious Diseases
12.11.2023
Despite our prevention efforts, some unlucky few may contract not just one of these viruses, but two at once or in close succession during the winter season. . WebMD Health News